Wall Street Zen Upgrades NeuroOne Medical Technologies (NASDAQ:NMTC) to Sell

NeuroOne Medical Technologies (NASDAQ:NMTC) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $2.23.

NeuroOne Medical Technologies Stock Performance

NASDAQ NMTC opened at $0.68 on Friday. The stock has a market cap of $34.36 million, a price-to-earnings ratio of -4.00 and a beta of 0.71. The business has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $0.80. NeuroOne Medical Technologies has a 52-week low of $0.40 and a 52-week high of $1.18.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The firm had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.47 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NMTC. Sio Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth approximately $2,390,000. Vanguard Group Inc. increased its holdings in NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after buying an additional 375,639 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in NeuroOne Medical Technologies during the fourth quarter worth $143,000. Virtu Financial LLC acquired a new stake in NeuroOne Medical Technologies in the third quarter valued at $88,000. Finally, Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.